RxDoctor Payments Data

Jason Chen, MD

Internal Medicine · Chicago, ILNPI 1972543239

Payments from drug & device makers

$988in general payments, 2019–2025

Across 38 payments — averaging $25.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$174
  • Abbott$147
  • Sunovion Pharmaceuticals Inc.$109
  • Novartis$107
  • AstraZeneca$103
  • Biogen$45
  • plus $303 from 11 others

What the payments were for

  • Food & beverage$988100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$988 in reported general payments places this provider in the 75th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$133,919
Medicare patients
81
Services billed
1,316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban40$30,790
TruvadaEmtricitabine/Tenofovir (Tdf)12$21,223
JanuviaSitagliptin Phosphate18$12,133
Atrovent HfaIpratropium Bromide22$10,114
JardianceEmpagliflozin12$9,081
Victoza 2-PakLiraglutide13$6,398
FarxigaDapagliflozin Propanediol12$6,342
SymbicortBudesonide/Formoterol Fumarate13$3,134
Advair HfaFluticasone Propion/Salmeterol13$3,122
Albuterol Sulfate HfaAlbuterol Sulfate82$2,321
Ventolin HfaAlbuterol Sulfate15$1,275
Atorvastatin Calcium99$1,001
Nifedipine ErNifedipine17$811
Metoprolol Succinate54$654
Amlodipine Besylate124$650

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$38$30,79040 claims
GileadTruvada$41$21,22312 claims
AstraZenecaFarxiga, Symbicort$103$9,47625 claims
Boehringer IngelheimJardiance$26$9,08112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →